Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in MetALD and ALD
Appointed Sarah Browne, M.D., as Chief Medical Officer to Help Lead the Next Stage of Clinical Development for DA-1726 and Vanoglipel
Full Data From the Phase 1 Parts 3A and 3B Expected in the First Quarter of 2027
CAMBRIDGE, Mass., Nov. 13, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate strategic update.
"The positive interim results from our Phase 1 Part 3B study of DA-1726, a novel oxyntomodulin $(OXM)$ analog and dual GLP-1/glucagon receptor agonist, were recently highlighted in an oral presentation at the Precision Liver Symposium. We believe these findings provide important clinical support for DA-1726's potential to treat metabolic dysfunction and alcohol-associated liver disease (MetALD), as well as alcohol-associated liver disease $(ALD)$," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "Most notably, after approximately 16 weeks, we observed a 68.1% placebo-adjusted reduction in liver fat, with all five of the participants with baseline steatosis achieving MRI-PDFF below 5%. These findings were accompanied by 13.5% placebo-adjusted weight loss, significant reductions in adipose tissue and relative preservation of lean tissue. Recently reported additional interim data also demonstrated a statistically significant 1.47 mg/dL placebo-adjusted reduction in uric acid after 16 weeks of treatment, further supporting DA-1726's liver-focused cardiometabolic profile. Based on these results, we are planning a 48-week Phase 2 study in up to 150 subjects with MetALD and ALD, targeted to begin in the second half of 2027. We also recently hosted an invitation-only KOL dinner during AASLD's The Liver Meeting 2026 featuring Dr. Rohit Loomba, a member of our Scientific Advisory Board. The event provided a valuable opportunity to gather leading experts in the field to discuss the evolving treatment landscape in MetALD and the significant unmet medical need we hope to address."
Mr. Kim continued, "Last month, we also expanded our clinical leadership team with the appointment of Sarah Browne, M.D., as Chief Medical Officer. Sarah brings more than 20 years of experience spanning clinical development, regulatory science and clinical medicine, including leading the development of pemvidutide, a dual GLP-1/glucagon receptor agonist, through Phase 2 and establishing Phase 3 development strategies. Her extensive experience developing therapies for metabolic and liver diseases will be particularly valuable as we prepare to move DA-1726 into Phase 2 development in MetALD and ALD. In parallel, we continue to advance vanoglipel, our G-protein-coupled receptor 119 (GPR119) agonist, in combination with resmetirom for MASH, with a Phase 2a proof-of-concept study targeted to begin in the first half of 2027."
Third Quarter 2026 and Subsequent Highlights
-- November 2026: Announced additional positive Phase 1 Part 3B interim data
demonstrating a statistically significant 1.47 mg/dL placebo-adjusted
reduction in uric acid after 16 weeks of treatment with DA-1726 (p<0.001),
further supporting its liver-focused cardiometabolic profile.
-- November 2026: Announced the presentation of preclinical data on DA-1726
at ObesityWeek 2026 in a poster entitled, DA-1726 Demonstrates Comparable
Weight Loss and Distinct Metabolic Profile Compared With Retatrutide.
-- November 2026: Presented positive DA-1726 Phase 1 Part 3B interim data in
an oral presentation at the Precision Liver Symposium, demonstrating a
68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted
weight loss at Day 109, with all five participants with baseline
steatosis achieving MRI-PDFF below 5%. Announced plans to initiate a
48-week Phase 2 study in MetALD and ALD.
-- October 2026: Appointed Sarah Browne, M.D., as Chief Medical Officer to
provide clinical and regulatory leadership as MetaVia advances DA-1726
and vanoglipel through their next stages of development.
-- September 2026: Announced preclinical tissue distribution findings for
DA-1726 showing the highest exposure in adipose tissue and prolonged
tissue retention, providing biological support for the reductions in
waist circumference observed clinically and DA-1726's once-weekly dosing
profile.
-- July 2026: Announced the completion of dose titration in the 16-week
Phase 1 Part 3 study of DA-1726, with all active patients successfully
reaching the highest planned dose levels of 48 mg and 64 mg.
Anticipated Clinical Milestones
-- DA-1726 in MetALD and ALD:
-- Full data from Phase 1 Parts 3A and 3B expected in the first
quarter of 2027.
-- Initiation of a 48-week, non-biopsy Phase 2 study in up to 150
subjects with MetALD and ALD is targeted for the second half of
2027.
-- Vanoglipel (DA-1241) in MASH:
-- MetaVia is currently working to schedule an End-of-Phase 2 meeting
with the FDA before the end of 2026 to discuss the clinical
development pathway for vanoglipel in combination with resmetirom.
-- Initiation of a randomized, 12-week Phase 2a non-biopsy
proof-of-concept study of vanoglipel in combination with
resmetirom is targeted for the first half of 2027.
Third Quarter Financial and Operating Results
-- Research and Development (R&D) Expenses were approximately $2.6 million
for the third quarter ended September 30, 2026, as compared to
approximately $1.9 million for the third quarter ended September 30,
2025. The increase of approximately $0.7 million was primarily
attributable to higher direct R&D expenses related to DA-1726 product
development, partially offset by $0.2 million in lower indirect
consulting expenses.R&D expenses were approximately $8.2 million for the
nine months ended September 30, 2026, as compared to approximately $6.6
million for the nine months ended September 30, 2025. The approximately
$1.6 million increase was primarily attributable to $2.0 million in
higher direct R&D expenses related to DA-1726 product development,
partially offset by (i) $0.2 million in lower indirect consulting
expenditures and (ii) $0.2 million in lower direct R&D expenses related
to vanoglipel product development.
-- General and Administrative (G&A) Expenses were approximately $2.1 million
for the third quarter ended September 30, 2026, as compared to
approximately $1.6 million for the third quarter ended September 30,
2025. The approximately $0.5 million increase was primarily attributable
to (i) $0.2 million in higher legal and professional fees, (ii) $0.2
million in higher consulting expenditures and (iii) $0.1 million in
higher employee compensation and benefits. G&A expenses were
approximately $5.9 million for the nine months ended September 30, 2026,
as compared to approximately $5.1 million for the nine months
ended September 30, 2025. The approximately $0.8 million increase was
primarily attributable to (i) approximately $0.3 million in higher
consulting expenditures, (ii) approximately $0.2 million in higher legal
and professional fees, (iii) approximately $0.1 million in higher
employee compensation and benefits costs and (iv) $0.2 million in higher
other G&A expenses, which was primarily related to higher franchise tax
expenses.
-- Total Operating Expenses were approximately $4.7 million for the third
quarter ended September 30, 2026, compared to approximately $3.5 million
for the third quarter ended September 30, 2025. The approximately $1.2
million increase was primarily attributable to higher R&D and G&A
expenses.Total operating expenses were approximately $14.1 million for
the nine months ended September 30, 2026, compared to approximately $11.7
million for the nine months ended September 30, 2025. The approximately
$2.4 million increase was primarily attributable to higher R&D and G&A
expenses for the nine months ended September 30, 2026.
-- Total Other Income was approximately $0.1 million for the third quarter
ended September 30, 2026, unchanged from the third quarter ended
September 30, 2025.Total other income was approximately $0.3 million for
the nine months ended September 30, 2026, as compared to approximately
$0.6 million for the nine months ended September 30, 2025. The
approximately $0.3 million decrease was primarily attributable to (i)
$0.1 million in lower gain from change in fair value of warrant
liabilities and (ii) $0.2 million in lower interest income, net, due to
lower balances of cash and cash equivalents and lower interest rates.
-- Net Loss was $4.6 million, or $0.69 per basic and diluted share, for the
third quarter ended September 30, 2026, based on 6,679,250 weighted
average shares of common stock outstanding, compared with a net loss of
$3.4 million, or $1.52 per basic and diluted share, based on 2,219,625
weighted average shares of common stock outstanding for the third quarter
ended September 30, 2025.Net loss was approximately $13.8 million,
or $2.36 per basic and diluted share for the nine months ended September
30, 2026, based on 5,830,258 weighted average shares of common stock
outstanding, compared with a net loss of approximately $11.0 million,
or $6.93 per basic and diluted share, based on 1,592,484 weighted average
Comments